Information Provided By: 
Fly News Breaks for April 17, 2015
MNTA, MYL, TEVA
Apr 17, 2015 | 08:00 EDT
After the FDA announced yesterday that it gave approval for Sandoz (NVS) and Momenta's (MNTA) generic 20mg Copaxone, Cowen said the approval of a generic version of Teva's (TEVA) drug should spur management to make a value-creating decision to acquire Mylan (MYL). The firm also believes in Teva's skill in protecting its Copaxone asset and said now is the time to pursue aggressive strategic actions. Cowen reiterated its Outperform rating and $100 price target on Teva shares.
News For TEVA;MYL;MNTA From the Last 2 Days
